Skip to main content
. 2018 May 17;103(8):1298–1307. doi: 10.3324/haematol.2017.171249

Figure 3.

Figure 3.

Kaplan-Meier estimated overall survival. Open circles indicate censored observations. Overall survival was calculated as the first date of study dosing until the date of death; patients without events were censored at the last contact. Per protocol, patients were followed for overall survival for two years after treatment discontinuation. Analysis includes data from a long-term extension study. IM-I: imatinib-intolerant; IM-R: imatinib-resistant; n: number.